HS-CSPC@EC2609B

CNS Pharma Revenue Grows 40.82% in Q1 2026, Net Loss Expands by 248.88%

Sino-Pharma Group's New Drug SYH2095 Receives FDA Approval for Clinical Trials

Sino Pharm HB1901 phase Ib/III trial for advanced malignant PEComa reaches primary endpoint

Jade Pharmaceutical Group Obtained NMPA Approval to Start Clinical Trials for SYS6051

Conerna Pharmaceutical-B and Stone Pharmaceutical Affiliate Reach Phase III Clinical Endpoint for HER2-Positive Breast Cancer Neoadjuvant Therapy

CMBI Raises Target Price for Stonepharm to HKD 8.7

CMBI Adjusts Profit Forecast and Target Price for Stone Pharmaceutical Group

ZTE Entertainment and Stone Pharmaceutical Group Announce Latest Shareholder Rights Disclosure

Jefferies Analyst Maintains Sell Rating on Stone Pharmaceutical Group

Jefferies Releases Report: Stone Pharmaceutical Group's 2022 Performance Under Pressure, Target Price Increased but 'Underperform' Rating Maintained

Citi Maintains Buy Rating for Stone Pharmaceutical Group but Cuts Target Price

Jade Pharmaceutical Group Discloses 2025 Annual Report with Revenue Growth

CSPC PHARMA released FY2025 earnings on March 25 During-Market (BJT), actual revenue HKD 28.42 B (forecast HKD 31.09 B), actual EPS HKD 0.3713 (forecast HKD 0.4834)

CSPC PHARMA released FY2025 Q4 earnings on March 25 During-Market (BJT), forecast revenue HKD 9.273 B, forecast EPS HKD 0.1543

Sino-Pharm Group reports 24.5% profit decline in FY2025 and proposes dividend distribution

Sino-Pharm Group's Aripiprazole Injection Receives Drug Registration Approval

Sino-Pharm Obtains Approval for 32mg Aprepitant Injection for Post-Operative Nausea and Vomiting

Stone Pharmaceutical's SYH2082 Injection Approved by China NMPA and FDA for Clinical Trials

CSPC PHARMA to Release FY2025 Earnings on March 25 During-Market (BJT), Forecast Revenue HKD 31.05 B, EPS HKD 0.4834

Jade Pharmaceutical Completes Gene Editing Research on ATTR and Publishes Findings

CONTEL

ISDN HOLDINGS

APEX ACE HLDG

MOST KWAI CHUNG

SHANGSHAN GOLD

NICHE-TECH SEMI

RIZHAO PORT JR

WKK INTL (HOLD)

HINGTEX HLDGS

RICH GOLDMAN

01093

520690

159837

513120

159570

516500

513700

512290

520880

159892

159992

520500

588130

159316

159849

512010

562050

510660

159506

CSPC Pharmaceutical Group reported a 40.82% year-on-year revenue increase to RMB 664.6 million for Q1 2026, but its net loss deepened to RMB 93.9 million. The company cautioned that these figures are unaudited and pertain only to its subsidiary, CSPC Innovation Pharmaceutical. Despite stable total assets, profitability metrics worsened, indicating potential cost pressures. Analysts maintain a Buy rating on the stock (HK:1093) with a price target of HK$13.05.

Tip Ranks

CSPC PHARMA

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CSPC Innovation

CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026

09995

688331

300765

China's pharmaceutical industry is rapidly evolving, with major companies like CSPC Pharmaceutical and RemeGen securing significant out-licensing agreements. The shift from low-cost manufacturing to high-value innovation is evident, particularly with the integration of AI in drug discovery. AI is compressing preclinical timelines and enhancing R&D capabilities. China now accounts for 30% of the global experimental drug pipeline and is a leader in antibody-drug conjugate projects. This growth has raised concerns among US lawmakers about China's potential dominance in the global pharmaceutical supply chain.

SCMP

REMEGEN

RemeGen

China’s drug makers are speeding up – will AI be their secret weapon?

CSPC Wins Shareholder Approval for Disposal of 30% Stake in Beijing Guoxin Huijin

CSPC Wins Shareholder Approval for Disposal of 30% Stake in Beijing Guoxin Huijin

06869

01347

06809

02513

01072

01177

01171

00883

06990

YOFC(06869) rose 18.94%, with a trading turnover 6.8 Billion HKD, and a year-to-date rose 334.8%. HUA HONG SEMI(01347) rose 14.68%, with a trading turnover 3.2 Billion HKD, and a year-to-date rose 22.5%. SBP GROUP(01177) fell 4.58%, with a trading turnover 848.3 Million HKD, and a year-to-date fell 2.3%. CSPC PHARMA(01093) fell 4.12%, with a trading turnover 857.3 Million HKD, and a year-to-date rose 10.4%.

Daily Top

YOFC

HUA HONG SEMI

MONTAGE TECH

KNOWLEDGE ATLAS

DONGFANG ELEC

SBP GROUP

YANKUANG ENERGY

CNOOC

SKB BIO

Top 5 HK Stock Gainers/Losers (>100B) (4.8)

CSPC Pharmaceutical Group (SEHK:1093) has received regulatory approval for its Aprepitant Injection, aimed at preventing postoperative nausea and vomiting. The stock has shown strong performance with an 80.59% total shareholder return over the past year. Currently trading at HK$9.71, the company has a P/E ratio of 25.1x, which is below its estimated fair P/E of 28.4x but above the sector average of 15.4x. Analysts suggest the stock may be undervalued, with a DCF model indicating a future cash flow value of HK$17.67. Investors are advised to consider both the potential and risks involved.

Simplywall

CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After Aprepitant Injection Approval

CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold rating by Bank of China with a price target of HK$9.10 on March 26, following a close of HK$8.16. UBS also assigned a Hold rating on March 25. Meanwhile, CMB International Securities maintained a Buy rating on the same day.

CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold Rating at Bank of China

Hong Kong stocks rose repeatedly, with the Hang Seng Index closing up 95 points at 24,951 points. Pharmaceutical stocks performed strongly, with CSPC PHARMA's share price rising nearly 14%. Several blue-chip companies announced their earnings, with CITIC Limited, Longfor, and Meituan seeing their share prices decline, while China Ping An and China Mobile's share prices increased. The total market turnover was HKD 263.081 billion

AASTOCKS

Harvest CNI Communication ETF

First Trust NYSE Arca Biotech Index Fd

"Hong Kong Stocks" Hang Seng Index closed up 95 points, pharmaceutical stocks led the rise, CSPC PHARMA surged nearly 14%

01772

03288

01276

01801

01339

02097

06690

03986

CSPC PHARMA(01093) rose 13.85%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 10.2%. GANFENGLITHIUM(01772) rose 9.26%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 43%. PICC GROUP(01339) fell 7.18%, with a trading turnover 746.4 Million HKD, and a year-to-date fell 19.6%. MIXUE GROUP(02097) fell 4.86%, with a trading turnover 354.1 Million HKD, and a year-to-date fell 30.2%.

GANFENGLITHIUM

HAITIAN FLAV

HENGRUI PHARMA

INNOVENT BIO

PICC GROUP

MIXUE GROUP

HAIER SMARTHOME

GIGADEVICE

Top 5 HK Stock Gainers/Losers (>100B) (3.27)

03317

02632

02616

01458

03339

03696

06127

09606

09887

XUNCE(03317) rose 24.26%, with a trading turnover 2.2 Billion HKD, and a year-to-date rose 273.3%. NEW VISION CO(02632) rose 23.93%, with a trading turnover 36.2 Million HKD, and a year-to-date rose 31.2%. CSTONE PHARMA-B(02616) rose 20.72%, with a trading turnover 613.5 Million HKD, and a year-to-date rose 58.1%.

XUNCE

NEW VISION CO

CSTONE PHARMA-B

ZHOU HEI YA

LONKING

INSILICO

JOINN

DUALITYBIO-B

LEADS BIOLABS-B

Top 10 HK Stock Gainers (3.27)

00HSI

03698

03690

002460

The Hang Seng Index closed at 24,951 points, up 95 points or 0.4%. The Hang Seng Tech Index reported 4,778 points, up 16 points or 0.3%. The total market turnover was HKD 263.081 billion. Among the actively traded heavyweights, Ping An rose by 2%, Xiaomi rose by 1.7%, and Meituan fell by 0.9%. CSPC Pharma rose over 13%, XUNCE hit a new high, and trading was active

Hang Seng Index

HUISHANG BANK

MEITUAN

Ganfeng Lithium

According to the "All-Day Express," the Hang Seng Index closed at 24,951 points, up 95 points; the Hang Seng Tech Index closed at 4,778 points, up 16 points. CSPC Pharma rose over 13%, XUNCE, Ganfeng Lithium, Weisheng Holdings, Qingsong Health, and HUISHANG BANK reached new highs with active trading

603127

The Hong Kong innovative drug sector continued to rise in the afternoon, with JOINN and CSPC PHARMA up over 10%, INNOVENT BIO up over 7%, and JUNSHI BIO and INNOCARE following suit

Wallstreetcn

InnoCare Pharma

Huaan Hang Seng Biotech ETF

JUNSHI BIO

Guotai CSI Hugangshen Innovative Drugs Industry ETF

INNOCARE

002594

515030

BYDDY

BYDDF

The Hong Kong stock market rose in the morning session, with the Hang Seng Index up 135 points or 0.55%, reporting at 24,992 points. The National Index rose 79 points or 1%, reporting at 8,469 points. Several blue-chip companies announced their earnings, with Meituan's stock price rising 1.7%, SMIC falling 0.5%, and China Mobile rising 0.4%. Pharmaceutical stocks generally rose, with CSPC PHARMA's stock price increasing by 9.6%. BYD rose 4.3%, and Leapmotor rose 5.5%. The total turnover of the market for the half-day was HKD 135.775 billion

Hua Xia CSI New Energy Vehicles ETF

BYD Company

BYD Company Limited

"Hong Kong Stocks" Hang Seng Index rises 135 points in half a day, BYD up over 4%, CSPC PHARMA rises by 10%

03393

02661

The Hang Seng Index closed at 24,992 points, up 135 points or 0.5%; the Hang Seng Tech Index reported 4,811 points, up 50 points or 1.1%. The National Index rose 79 points or 1.0%, closing at 8,469 points. Among the active blue-chip stocks, Meituan rose 1.7%, Xiaomi rose 1.7%, Alibaba rose 0.3%, and Tencent slightly fell by 0.1%. CSPC Pharma had the largest increase, rising 9.6%, while XUNCE reached a new high, rising 22.9%

WASION HOLDINGS

QINGSONG HEALTH

The "Half-Day Express" reports that the Hang Seng Index closed at 24,992 points, up 135 points; the Hang Seng Tech Index closed at 4,811 points, up 50 points. CSPC Pharma rose over 9%, XUNCE, WASION HOLDINGS, Ganfeng Lithium, QINGSONG HEALTH, and HUISHANG BANK reached new highs

Hot trading industry trends on August 7 and related Hong Kong semiconductor stocks. Hong Kong semiconductor stocks opened lower in early trading but then surged strongly, with Innoscience gaining over 11%, and industry leader SMIC rising over 3%. Core logic: On the news front, on August 1, Innoscience officially responded to rumors of collaboration with NVIDIA. The announcement stated that the company has recently partnered with global AI technology leader NVIDIA to jointly promote the large-scale implementation of the 800VDC (800-volt direct current) power architecture in AI data centers. Clear signals of a cyclical bottom: Global semiconductor inventory reduction is nearing its end...

NVIDIA

SMIC

SMIC HK SDR 5to1

SJM HOLDINGS

MGM CHINA

FIT HON TENG

WUXI APPTEC

WuXi AppTec

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

GALAXY ENT

Hot Trades in Hong Kong Stocks (8.7)｜ Chip Stocks Rebound Strongly, Apple Supply Chain Follows; Xiaomi and Pharmaceuticals Retreat Under Pressure

HS-CSPC@EC2609B(28589.HK)

CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026

China’s drug makers are speeding up – will AI be their secret weapon?

CSPC Wins Shareholder Approval for Disposal of 30% Stake in Beijing Guoxin Huijin

Top 5 HK Stock Gainers/Losers (>100B) (4.8)

CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After Aprepitant Injection Approval